CoChat

Th9 cells promote antitumor immune responses in vivo

Open access
Lu, Yong, Hong, Sungyoul, Li, Haiyan, Park, Jungsun, Hong, Bangxing, Wang, Lijuan, Zheng, Yuhuan, Liu, Zhiqiang, Xu, Jingda, He, Jin, Yang, Jing, Qian, Jianfei, Yi, Qing · 2012 · Journal of Clinical Investigation

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Th9 cells are a subset of CD4+ Th cells that produce the pleiotropic cytokine IL-9. IL-9/Th9 can function as both positive and negative regulators of immune response, but the role of IL-9/Th9 in tumor immunity is unknown. We examined the role of IL-9/Th9 in a model of pulmonary melanoma in mice. Lack of IL-9 enhanced tumor growth, while tumor-specific Th9 cell treatment promoted stronger antitumor responses in both prophylactic and therapeutic models. Th9 cells also elicited strong host antitumor CD8+ CTL responses by promoting Ccl20/Ccr6-dependent recruitment of DCs to the tumor tissues. Subsequent tumor antigen delivery to the draining LN resulted in CD8+ T cell priming. In agreement with this model, Ccr6 deficiency abrogated the Th9 cell-mediated antitumor response. Our data suggest a distinct role for tumor-specific Th9 cells in provoking CD8+ CTL-mediated antitumor immunity and indicate that Th9 cell-based cancer immunotherapy may be a promising therapeutic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci65459

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

Metadata

Authors
Lu, Y., Hong, S., Li, H., Park, J., Hong, B., Wang, L., Zheng, Y., Liu, Z., Xu, J., He, J., Yang, J., Qian, J., & Yi, Q.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Yi, Qing
Venue
Journal of Clinical Investigation
Published
2012-10-15
Volume
122
Issue
11
Pages
4160-4171
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2066906123
Cited by
361
References
50
Citations by year
2026: 13 · 2025: 22 · 2024: 19 · 2023: 25 · 2022: 27 · 2021: 24 · 2020: 33 · 2019: 37 · 2018: 35 · 2017: 34 · 2016: 34 · 2015: 26 · 2014: 18 · 2013: 13 · 2012: 1
FWCI
8.08
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Multiple Myeloma Research Foundation
  • Commonwealth Foundation
  • Leukemia and Lymphoma Society
  • University of Texas MD Anderson Cancer Center
  • National Cancer Institute (R01CA138402, R01CA138398, R01CA163881, P50CA142509, P30CA016672)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
Th9 cells, IL-9, antitumor immunity, pulmonary melanoma, CD8+ cytotoxic T lymphocytes, dendritic cell recruitment, tumor antigen delivery, draining lymph nodes, cancer immunotherapy, CD4+ T cells
MeSH terms
Animals, Dendritic Cells, T-Lymphocytes, Helper-Inducer, Immunity, Cellular, Immunotherapy, Lung Neoplasms, Melanoma, Interleukin-9, Antigen Presentation, Mice, Knockout, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice, Receptors, CCR6, Chemokine CCL20

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.